For semaglutide, common maintenance doses range from 0.25 mg to 1.0 mg weekly, down from the therapeutic 1.7 to 2.4 mg
Patients who continued treatment with arGLP-1 sustained their excess weight loss over time, with positive outcomes observed even up to 34 years of continuous therapy
Complex Manufacturing and Globalized Supply Chains: Peptide synthesis, formulation, device integration (for injectables), and cold chain logistics introduce layers of complexity
While not yet widely available, it represents the future of GLP-1-based weight loss treatments
It sits between the 1.0 mg step and the 1.7 mg step on the standard Wegovy escalation schedule, which makes it a moderate dose that many people use during the titration phase
This product has been manufactured in a cGMP facility